India has a great potential to become global hub for manufacturing and services for almost anysector,with pharma leading

With an aim of enhancing their footprint on the Indian Subcontinent to become more responsive to the ever changing and evolving needs of the pharma industry,Steriline and INCOME recently announced their union.In an interaction with Express Pharma, Federico Fumagalli ,Commercial Director,Steriline Srl, Vishesh Parekh ,Managing Partner, INCOME and Chiranjeevi Kondapaka ,CEO,Steriline Asia talks about the objectives of this union and motivation behind this decision

Could you provide us with an overview of the union and the motivations behind this decision?

Vishesh Parekh: INCOME and Steriline had been working together since over a quarter century. It is natural that, after such a long association, the bonds which develop go beyond just a simple Agent – Principal relationship and become much deeper and stronger. We have decided to formalise these bonds so that the strengths of both the organisations can be leveraged to move ahead in a much faster manner.

Could you provide some insights into the potential benefits that the union will bring to both companies and the pharma industry as a whole?

Federico Fumagalli: The idea behind any such joining of hands is always to make the resultant is bigger than the sum of the individuals! Each organisation had its own inherent strengths and drawbacks. I believe that the inherent strengths get multiplied and the weaknesses neutralised.

Our customers can certainly expect much better offerings from us in terms of products and services. These will come from a major recruitment drive we are undertaking presently where we are actively looking for a large number of Software Engineers, Mechanical Engineers, Design Engineers.

Response time to customers are expected to further improve with such a large team in place. Software support, which used to happen from Italy and was a challenge due to different time zones will now become a local support.

Overall, I believe, Steriline changes are certain to be expected, but I believe these would be positive changes which will lead to growth and development of not only the organisations, but individuals too. member of a Pan European organisation which will bring in some of the best HR practices followed by them worldwide. realignment of roles as new team members join in, but this would certainly be for creating value offerings to all stake holders

Asia will be able to rise not only to, but beyond customer expectations in many ways.

With the merger, what changes can employees and stakeholders expect? Will there be any restructuring or realignment of roles?

Chiranjeevi Kondapaka: they say, the only thing Permanent in Life is Change!

Looking ahead, what are the long-term goals and aspirations?

Kondapaka: that India has a great potential to become a global hub for manufacturing and services for almost any sector, with Pharma leading.

Steriline Asia is uniquely positioned to leverage this potential of India and become a proud part of the country’s growth story.

As a first stage, Steriline

Asia shall cater to the service and support needs of all our clients, not only in India but pan Asia. We hope to move ahead and utilise the “soft power” of India to customise softwares and the development of AI for our machines. Design and manufacture, we believe would follow as a natural step.

Where does India fit into the company's global vision? Any big tie-ups or investments, in the offing?

Fumagalli: I believe the above answers clearly indicate that India is a priority in our Global

ApplicationsforSolid

DosageForms:

Binder

Filmcoating

Soliddispersioncarrier

Features:

Lowviscosity

Watersoluble

Nonionicpolymer

Shin-EtsuChemicalTyloseIndiaPvt.Ltd. OfficeNo.B,7thFloor,DBuilding,MBCPark, GhodbunderRoad,Kasarwadavali, Thane(West)-400615India.

Tel.:+912262833001Email:pharmaindia@setylosein.com

Plans. At the moment we have a subsidiary in the USA, but this is just limited to sales and support for our US based customer. Our operations in India are envisaged to grow much beyond supporting local Indian customers as I explained earlier. August

Pharma experts and leaders unite to unravel opportunities for India Pharma Inc and explore Chandigarh's potential to fuel India's aspirations to be a global pharma powerhouse

By Lakshmipriya Nair

The Indian pharma industry is in the midst of a paradigm shift from volume-based to valuedriven strategies. Recognising the significance of this transition, Express Pharma is organising a series of "Pharma Summits" across the country's key pharma centers. These events are strategically designed to unlock new opportunities and navigate the intricacies of this evolving landscape. From cost and competitive pressures to cutting-edge scientific advancements and digital innovations, the summits examine factors driving value in the pharma ecosystem.

The latest in this series, Chandigarh Pharma Summit 2023 was successfully hosted by Express Pharma recently. Under the theme, "Volume to Value Leadership: Opportunities and Challenges for India Pharma Inc”, it provided a platform for industry leaders and game changers to converge and engage in an exchange of ideas, insights, and experiences pertaining to the latest trends, challenges, and opportunities in the pharma sector. It also showcased why Chandigarh, with a conducive business climate, access to skilled manpower, and good infrastructure, presents an opportunity for pharma companies to expand their horizons.

In this article, we delve into the highlights of the Chandigarh Pharma Summit 2023, and showcase the key takeaways and insights from the presentations and discussions at the event.

Leaders must be open to embracing change

Chandigarh Pharma Summit 2023 commenced with a very impactful inaugural address by Dr Sanjit Singh Lamba, Managing

Partner, Trillyum Consulting and Advisory.

His address shed light on the immense growth potential of India Pharma Inc and emphasised India’s crucial role in the pharmerging markets. To harness this

Future readiness of pharma facilities will be determined by compliance, quality and automation.Digitalisation will enable progress across all these areas potential effectively, Dr Lamba stressed the importance of a value-driven approach, which can be achieved through strategic investments, key collaborations, intellectual property creation, and a patient-centric focus.

Head-Pharma of Laghu Udyog Bharati and President of the Himachal Drugs Manufacturers Association, delivered a compelling keynote address at the Chandigarh Pharma Summit 2023, offering valuable insights from the regulatory perspective.

In his address, Dr Gupta highlighted the regulatory challenges faced by the pharma industry and emphasised that regulatory compliance plays a vital role in ensuring the safety and efficacy of pharma products. Proper documentation and effective data management were underscored as essential to build and sustain a culture of quality and compliance within the industry.

The session shed light on how disparities in manufacturing practices and varying quality standards, coupled with ineffective documentation and lack of transparency in communication, were hindering the industry's growth. To overcome these hurdles, Dr Gupta advised leaders to collaborate closely with regulatory authorities and proactively address compliance issues. He accentuated that this approach is crucial to maintain trust and credibility among stakeholders.

Dr Lamba also spoke on the significance of a qualityoriented approach, substantial investments in research and development, and fostering an inn ovation- driven mindset for sustained progress in this industry. He also highlighted the impor- tance of building health infrastructure, skill development, regulatory compliance, diversifying product portfolios to mitigate risks, and promoting training and awareness programmes.

A key message from his address was that leaders need to be open to change and perceive disruptions as opportunities for growth, rather than obstacles. Dr Lamba also advocated the need to instill a culture of continuous learning within organisations to adapt successfully in an ever-changing business landscape.

The central take away from his session was that transformation of Indian pharma companies from a volume-driven approach to value-driven progress requires focus on quality, innovation, collaboration, and specialisation.

Dr Lamba's insights provided guidance for India Pharma Inc's continued success and leadership in the global pharma market.

Regulatorycompliance is crucial for India Pharma Inc’s reputation

Dr Rajesh Gupta, All India

During the address, Dr Gupta also brought attention to the issue of non-standard quality (NSQ) products, which have been negatively impacting the industry's global standing. He stressed that regulatory compliance, transparent communication, and strict adherence to guidelines are vital to uphold India Pharma Inc's reputation in the international arena.

Dr Gupta's address served as a reminder for leaders to take proactive measures in aligning with regulations and fostering a culture of quality and transparency to drive the industry's progress and success.

Qualityshould be a top leadership priority

Dr Prahalad Singh Maan,

Global QMS & Quality Compliance Director at Reckitt, delved into the crucial topic of nurturing quality leadership amidst disruption. Participants gained valuable insights on tackling challenges posed by disruptions and honing effective leadership to elevate quality standards in their organisations.

He pointed out that technological advancements have empowered consumers, granting instant access to expert data with a single click. Consequently, early warning systems play a pivotal role in promptly addressing quality issues, enabling organisations to remain responsive and proactive.

Maan's session also underscored that repeated disruptions can erode the culture of quality in organisations due to shifting priorities, rapid changes, and evolving expectations. To counteract this, quality should be a leadership priority, integrated into decision-making and actions.

A key takeaway from his session was the significance of leaders "walking the talk" on quality, setting powerful examples for their teams and fostering a culture of excellence and continuous improvement. Leaders should also prioritise evaluating and recognising employees' contributions to quality, reinforcing their commitment to maintaining high standards.

Regulatorycompliance is an ongoing process that requires vigilance and continuous improvement

Girraj Tripathi, Sr GM, and Site Quality Head at Sun Pharma shed light on the evolving regulatory landscape, stressing the importance of proactive compliance measures. Leaders must prioritise adherence to guidelines, transparent communication with regulatory bodies, and continuous improvement to ensure product safety and efficacy while staying ahead of changing regulations.

The session addressed the regulatory challenges faced by the pharma industry, including evolving guidelines, complex approv al processes, and global variations in regulations. He said, collaboration between industry stakeholders, proactive compliance strategies, and leveraging technology for streamlined regulatory submissions and tracking can help overcome these challenges.

Tripathi emphasised the crucial role of management and leaders in maintaining product quality, compliance, and fostering a culture of ex- cellence. Data integrity and reliability were highlighted as critical aspects, requiring proper protocols, training, and oversight to safeguard accurate information within

Monitorenvironmentalparameters-butdoitright!

August 2023 testoDataLoggers:rightdataloggerforeveryapplication.

● Dataloggersforcoldstorages,warehouses,cleanrooms,andbloodbanks,etc.

● fromanywhere.

WiFidataloggersforrealtimedatamonitoringandeaseofmeasurementvalueaccess

●

Analysisbysoftware:readoutdataoncomputer

Mobiledataloggersfordatastorageandfrequentread-outduringtransport

●

● EN12830,CFRandHACCPcompliantloggers

Applications

LowtemperaturefreezermonitoringinlabsMonitoringstorageinpharmacies || RefrigeratormonitoringinhospitalsDatamonitoringincleanroomsIndoorclimatemonitoring || Mappinginhigh-baywarehouses | organisations. The session also emphasised the importance of embracing technological advancements, regulatory harmonisation, and promoting cooperation among regulatory bodies.

The key message conveyed was that the industry must adopt a proactive approach to keep pace with evolving regulatory requirements, and process automation can greatly aid in streamlining compliance efforts.

Embracing innovation in pharma packaging is vital become future

Shivaji Chakraborty, Asst. General Manager, Fresenius Kabi Oncology spoke on the topic, ‘Shaping the new normal of pharma packaging’, which focused on the evolving trends and advancements in pharma packaging.

He identified and elaborated on factors driving the evolution of pharma packaging, including changes in consumer behavior, shifting market dynamics, aging

CONTRIBUTOR’S CHECKLIST

❒ Express Pharma accepts editorial material for regular columns and from pre-approved contributors / columnists.

❒ Express Pharma has a strict non-tolerance policy of plagiarism and will blacklist all authors found to have used/refered to previously published material in any form, without giving due credit in the industryaccepted format.All authors have to declare that the article/column is an original piece of work and if not,they will bear the onus of taking permission for re-publishing in Express Pharma.

❒ Express Pharma's prime audience is senior management and pharma professionals in the industry.Editorial material addressing this audience would be given preference.

❒ The articles should cover technology and policy trends and business related discussions.

❒ Articles for columns should talk about concepts or trends without being too company or product specific.

❒ Article length for regular columns: Between 1200 - 1500 words.These should be accompanied by diagrams,illustrations,tables and photographs,wherever relevant.

❒ We welcome information on new products and services introduced by your organisation for our various sections: Pharma Ally (News,

Girraj Tripathi

Senior General Manager and Site Quality Head, Sun Pharma

population, inclusive packaging to cater to diverse demographics, and a growing focus on sustainability. He emphasided that pharma packaging has undergone significant changes to align with shifting market dynamics, and serves various key functions including protection, containment, branding, brand protection and sustainability.

He concluded the session by informing the audience that the future of pharma will be characterised by tamperevident features, authentication measures, and improved communication with consumers. It will also serve as a reminder to promote medication adherence and emphasise sustainability through eco-friendly materials and practices.

An important message from his session was that innovative pharma packaging can meet the changing needs of the industry. Creative packaging solutions can enhance product safety, extend shelf life and improve patient experience.

Products,Value Add),Pharma Packaging and Pharma Technology Review sections.Related photographs and brochures must accompany the information.

❒ Besides the regular columns,each issue will have a special focus on a specific topic of relevance to the Indian market.

❒ In e-mail communications,avoid large document attachments (above 1MB) as far as possible.

❒ Articles may be edited for brevity,style,and relevance.

❒ Do specify name,designation,company name,department and e-mail address for feedback,in the article.

❒ We encourage authors to send their photograph.Preferably in colour,postcard size and with a good contrast.

Email your contribution to: The Editor, Express Pharma, Business Publications Division,The Indian Express (P) Ltd, Mafatlal Centre,7th floor,Ramnath Goenka Marg, Nariman Point,Mumbai 400021 viveka.r@expressindia.com viveka.roy3@gmail.com

Charting the path to progress

The Chandigarh Pharma Summit 2023 provided valuable insights and learnings on various pivotal topics ranging from regulatory compliance and manufacturing capabilities to product solutions and quality leadership. During the summit, industry professionals exchanged ideas, addressed regulatory hurdles, and explored innovative breakthroughs.

Each session highlighted critical aspects for success in the industry. It also showcased the sector's potential for growth by embracing value-driven strate-